Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

, an oncogene mutated in nearly one third of human cancers, remains a pharmacologic challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant. Here, we report that selective inhibition of the protein tyrosine phosphatase, SHP2, can impair the proli...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2019-12, Vol.18 (12), p.2368-2380
Hauptverfasser:	Hao, Huai-Xiang, Wang, Hongyun, Liu, Chen, Kovats, Steven, Velazquez, Roberto, Lu, Hengyu, Pant, Bhavesh, Shirley, Matthew, Meyer, Matthew J, Pu, Minying, Lim, Joanne, Fleming, Michael, Alexander, LeighAnn, Farsidjani, Ali, LaMarche, Matthew J, Moody, Susan, Silver, Serena J, Caponigro, Giordano, Stuart, Darrin D, Abrams, Tinya J, Hammerman, Peter S, Williams, Juliet, Engelman, Jeffrey A, Goldoni, Silvia, Mohseni, Morvarid
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!